Table 2 Univariate and Multivariate Analyses progress-free survival prognosis of NSCLC EGFR-mutated patients

 <70

1

1

 ≥70

0.69(0.41,1.16)

0.1598

0.65 (0.34, 1.23)

0.1872

 female

1

 male

1.13(0.73, 1.75)

0.5869

 0

1

1

 1

1.28 (0.73, 2.24)

0.3838

1.09 (0.59, 2.01)

0.7920

 2

0.88 (0.42, 1.83)

0.3838

0.85 (0.38, 1.93)

0.6983

 No

1

 Yes

0.85 (0.45, 1.61)

0.6175

 Adenocarcinoma

1

 Others

1.37 (0.50, 3.76)

0.5419

 IVA

1

1

 IVB

1.62 (0.95, 2.77)

0.5419

1.29 (0.63, 2.65)

0.4792

 No

1

 Yes

1.15 (0.75, 1.77)

0.5156

 No

1

1

 Yes

1.58 (1.01, 2.50)

0.0471

1.30 (0.71, 2.36)

0.3976

 No

1

1

 Yes

1.40 (0.74, 2.65)

0.2976

1.38 (0.65, 2.93)

0.3981

 No

1

1

 Yes

0.67 (0.43, 1.05)

0.2976

0.71 (0.43, 1.15)

0.1665

 No

1

1

 Yes

1.29 (0.81, 2.05)

0.2897

1.34 (0.81, 2.21)

0.2551

 19del

1

1

 21-L858R

1.06 (0.68, 1.64)

0.8086

1.37 (0.82, 2.27)

0.2288

 other

0.75 (0.27, 2.12)

0.5906

1.41 (0.40, 4.94)

0.2288

 No

1

1

 Yes

0.41 (0.13, 1.32)

0.1367

0.58 (0.16, 2.10)

0.4068

 No

1

1

 Yes

1.18 (0.75, 1.87)

0.4664

0.94 (0.56, 1.60)

0.8298

 No

1

1

 Yes

1.27 (0.80, 2.01)

0.4664

1.08 (0.62, 1.87)

0.7893

 1 generation TKI

1

1

 2 generation TKI

0.93 (0.47, 1.83)

0.8289

0.64 (0.28, 1.46)

0.2927

 3 generation TKI

0.41 (0.23, 0.73)

0.0026

0.39 (0.20, 0.77)

0.0063

 1 generation TKI+ Anlotinib

0.64 (0.26, 1.61)

0.8289

0.54 (0.20, 1.44)

0.2183

 No

1

1

 Yes

1.15 (0.66, 2.01)

0.6300

1.38 (0.73, 2.58)

0.3210